• 1-year OS = 74%, 2-year OS 52%• 1-year and 2-year distant BrM recurrence rates (per patient) after SRS = 34% and 53%• 1-year and 2-year rates of local tumor control (per lesion) = 97% and 95%• MVA proportional hazards analyses found being EGFR-TKI naïve• associated with longer OS (HR: 0.42, P < 0.001), a lower distant intracranial recurrence rate (HR: 0.61, P = 0.037) and higher local tumor control rate (HR: 0.28, P = 0.001). Here, EGFR is linked to neoplasm.